## Osteoclasts Protect Bone Blood Vessels Against Senescence through the Angiogenin/Plexin-B2 Axis

Xiaonan Liu, Yu Chai, Guanqiao Liu, Weiping Su, Qiaoyue Guo, Xiao Lv, Peisong Gao, Bin Yu, Gerardo Ferbeyre, Xu Cao, and Mei Wan



Supplementary Figure 1 Senescent Cells Were Not Detected in Diaphysis of Long Bone in Young Mice after GC Treatment. Three-week-old male *BALB/c* mice were treated with methylprednisolone (MPS, 10 mg/m<sup>2</sup>/day) or vehicle by daily intraperitoneal injection for 3 weeks. Representative images of senescence-associated  $\beta$ -galactosidase (SA- $\beta$ Gal) staining (blue) (a) and quantification (b) of SA- $\beta$ Gal<sup>+</sup> cells (N. SA- $\beta$ Gal<sup>+</sup> cells/Ar) in diaphysis of femoral bone. n=5-6. Data are represented as mean  $\pm$  s.e.m. Ar, tissue area. ns, not significant as determined by two-tailed Student's *t*-tests.



Supplementary Figure 2 Percentage of Vascular Endothelial Cells Was Decreased in Metaphysis of Long Bone in Young Mice after GC Treatment. (a-b) Three-week-old *BALB/c* mice were treated with methylprednisolone (MPS, 10 mg/m<sup>2</sup>/day) or vehicle by daily intraperitoneal injection for 3 weeks. Percentage of CD144<sup>+</sup> or Emcn<sup>+</sup> cells was calculated by flow cytometry analysis in (a) and (b), respectively. n=5 mice. Data are represented as mean  $\pm$  s.e.m. Ar, tissue area. \*p<0.05, \*\*p<0.01 as determined by two-tailed Student's *t*-tests.



Emcn/SA-βGal

Supplementary Figure 3 Vascular Endothelial Cells Have Increased SA- $\beta$ Gal Activity after GC Treatment. (a-b) Three-week-old *BALB/c* mice were treated with MPS at 10 mg/m<sup>2</sup>/day or vehicle by daily intraperitoneal injection for 3 weeks. Representative images of SA- $\beta$ Gal staining (white) and immunostaining of endomucin (Emcn, red) in primary spongiosa of femoral bone in (a). Images in upper panels are lower power with boxes outlining the area of higher power in bottom panels. Percentage of SA- $\beta$ Gal-expressing vessels in primary spongiosa was quantified in (b). n=6 mice. Data are represented as mean  $\pm$  s.e.m. GP, growth plate. \*\*p< 0.01 as determined by two-tailed Student's *t*-tests.



Supplementary Figure 4 Osteoclast Lineage Cells in Femoral Metaphysis Are Not the Major Senescent Cell Type in Young Mice after GC Treatment. (a-b) Three-week-old *BALB/c* mice were treated with MPS at 10 mg/m<sup>2</sup>/day or vehicle by daily intraperitoneal injection for 3 weeks. TRAP- (pink) and SA- $\beta$ Gal- (blue) co-staining of femur metaphysis sections was performed in (a). Quantitative analysis of the percentage of SA- $\beta$ Gal-expressing TRAP+ cells is shown in (b). n=5 mice. Data are represented as mean  $\pm$  s.e.m. ns, not significant as determined by two-tailed Student's *t*-tests.



Supplementary Figure 5 Osteoprogenitors but Not Vascular Endothelial Cells Undergo Apoptosis in Femoral Metaphysis of Young Mice after GC Treatment. (a-d) Three-week-old *BALB/c* mice were treated with MPS at 10 mg/m<sup>2</sup>/day or vehicle by daily intraperitoneal injection for 3 weeks. Femoral bone tissue sections were subjected to TUNEL assay and immunostaining of Emcn (a) or Osx (c). Apoptotic cells were in green and Emcn<sup>+</sup> or Osx<sup>+</sup> cells were in red. DAPI stains nuclei blue. Percentage of TUNEL<sup>+</sup>Emcn<sup>+</sup> vascular endothelial cells and TUNEL<sup>+</sup>Osx<sup>+</sup> osteoprogenitors were shown in (b) and (d), respectively. n=5 mice. Data are represented as mean  $\pm$  s.e.m. GP, growth plate. Ar, tissue area. \*\*p< 0.01, ns, not significant as determined by two-tailed Student's *t*-tests.



Supplementary Figure 6 Histomorphometry Analysis of Osteoblastic Bone Formation in *p16*-iKO Mice. (a-e) Three-week-old *Cdh5-Cre*<sup>ERT2</sup>;*p16*<sup>flox/flox</sup> (*p16*-iKO) mice and *p16*<sup>flox/flox</sup> (WT) mice were treated as described in Figure 3 and killed at 6 weeks of age. Bone histomorphometric analysis of femoral metaphysis was performed. Number of osteoblasts per bone perimeter (Ob.N/B. Pm) and osteoblast surface per bone surface (Ob.S/BS) were measured in (a) and (b), respectively. Number of osteoclasts per bone perimeter (Oc.N/B. Pm) and osteoclasts per bone perimeter (Oc.N/B. Pm) and osteoclasts per bone perimeter (Oc.N/B. Pm) and osteoclast surface per bone surface per bone surface (Oc.S/BS) were measured in (c) and (d), respectively. P1NP concentration was measured in blood samples (e). n=5-7 mice. Data are represented as mean  $\pm$ s.e.m. \*\*p<0.01, ns, not significant as determined by one-way ANOVA with post hoc Tukey test.



Supplementary Figure 7 GC Treatment Decreases the Number of Osteoclast-Lineage Cells in Femoral Metaphysis in Young Mice. (a-f) Three-week-old *BALB/c* mice were treated with MPS at 10 mg/m<sup>2</sup>/day or vehicle by daily intraperitoneal injection for 2 weeks. Immunofluorescence staining of femoral bone sections was performed using antibodies against TRAP (a), VPP3 (c), and F4/80 (e), respectively. DAPI stains nuclei blue. Quantified numbers of TRAP<sup>+</sup> cells, VPP3<sup>+</sup> cells, and F4/80<sup>+</sup> cells in metaphysis are shown in (b), (d) and (f), respectively. GP, growth plate. Ar, tissue area. n=5-6 mice. Data are represented as mean  $\pm$ s.e.m. \*\*p< 0.01, ns, not significant as determined by two-tailed Student's *t*-tests.



**Supplementary Figure 8 Apoptosis of Endothelial Cells Were Not Induced by PLXNB2 Knockdown. (a)** HUVECs were transfected with scrambled control siRNA (siCTRL) or PLXNB2 specific siRNA (siPLXNB2). Thirty-six hours later, the cells were treated with 200 ng/ml rhANG or vehicle for another 12 hours. TUNEL assay was performed, and the apoptotic cells are shown in red.



Supplementary Figure 9 rhANG Attenuates GC-impaired Osteogenesis in Femoral Metaphysis in Young Mice. (a-h) Three-week-old *BALB/C* mice were treated with vehicle, MPS alone at 10 mg/m<sup>2</sup>/day or MPS plus rhANG (1  $\mu$ g/day) by daily intraperitoneal injection for 4 weeks. Representative images of OCN<sup>+</sup> osteoblasts on trabecular bone surface in (a). Number of osteoblasts per bone perimeter (Ob.N/B. Pm) and osteoblast surface per bone surface (Ob.S/BS) were measured in (b) and (c), respectively. Representative images of Safarin O-fast green (SOFG) staining in primary spongiosa of femoral bone in (d). Number of osteocytes(Osteocyte.N/Ar) were quantified in (e). Representative images of TRAP<sup>+</sup> osteoclasts on trabecular bone surface in (f). Number of osteoclasts per bone perimeter (Oc.N/B. Pm) and osteoclast surface per bone surface (Oc.S/BS) were measured in (g) and (h), respectively. n=6-10 mice. Data are represented as mean ±s.e.m. \*\*p<0.01, ns, not significant as determined by one-way ANOVA with post hoc Tukey test.



## Supplementary Figure 10 rhANG Rescues GC-Induced Growth Retardation Phenotype in Young Mice. (a-g) Three-week-old *BALB/c* mice were treated with vehicle, MPS alone at 10 mg/m<sup>2</sup>/day or MPS plus rhANG (1 $\mu$ g/day) by daily intraperitoneal injection for 4 weeks. (a) Tail length (cm) was measured each week during the treatment. (b) Measurements of body weight in each group. (c) Hematoxylin and eosin staining of representative sections of distal femoral growth plates. Measurements of the length of three different chondrocyte zones in the rhANG, MPS and MPS+rhANG group relative to the vehicle control group in (d), (e) and (f), respectively. (g) Femur length was calculated by measuring the distance between the apex of femoral head and the most distal point of subchondral bone in distal femur. GP, growth plate; RZ, resting zone; PZ, proliferating zone; and HZ, hypertrophic zone. n=6-10 mice. Data are represented as mean $\pm$ s.e.m. \*p< 0.05, \*\*p< 0.01 as determined by one-way ANOVA with post hoc Tukey test.



Supplementary Figure 11 Gating strategy for in vivo FACS analysis experiments.

qRT-PCR Primers		
Gene	Forward	Reverse
ki67	ACCGTGGAGTAGTTTATCTGGG	TGTTTCCAGTCCGCTTACTTCT
p16	GAAAGAGTTCGGGGCGTTG	GAGAGCCATCTGGAGCAGCAT
p53	ATCGCCTTCGACATCATCGC	CCCCATGCGTACTCCATGAG
p21	AGAAGGTACTTACGGTGTGGT	GAGAGATTTCCCGAATTGCAGT
ang	TTGATCTTCGTGCTGGGTCTGG	CTCTGTAAGGGCTTCCATTCGC

Supplementary Table 1 Primers used for qRT-PCR.